Common questions
Can you take cagrilintide and tirzepatide together?
Yes, but not on the same starting day. Standard community protocols run tirzepatide alone for the first 8 weeks (2.5 → 5 mg/week) to confirm GI tolerance, then add cagrilintide at 0.25 mg/week starting Week 9. Both compounds are once weekly. From Week 9 onward, most users dose both on the same day at different injection sites.
How much cagrilintide do you take with tirzepatide?
Most community protocols start cagrilintide at 0.25 mg/week once tirzepatide is established, then step up every 4 weeks to 0.5, 1.0, 1.7, and 2.4 mg/week. Tirzepatide titrates separately from 2.5 mg up to 15 mg/week.
How far apart should I inject cagrilintide and tirzepatide?
Most users inject both on the same day, a few minutes apart at different sites. There is no required time gap. Same day is simpler, but some users split them—tirzepatide Monday and cagrilintide Thursday—to spread out GI side effects during titration. Both compounds have half-lives around 5–8 days, so splitting by a few days does not change overall coverage much.
Can I inject cagrilintide and tirzepatide at the same port (same injection site)?
No. Use different injection sites for each compound—for example, tirzepatide in the abdomen and cagrilintide in the thigh or upper arm. Different sites reduce local irritation, lower the risk of stacked injection-site reactions, and help you tell which compound is causing any reaction. Never mix the two compounds in one syringe.
When does cagrilintide appetite suppression kick in?
Cagrilintide has a long half-life (about 7–8 days), so it takes time to build up. Most users report noticeable appetite suppression by Week 2–3 after starting it. Some report changes within the first week. At the starting 0.25 mg/week dose, effects are usually mild. Stronger satiety effects typically appear after stepping up to 0.5–1.0 mg/week.
Is there any combination data for cagrilintide + tirzepatide?
Yes—one preclinical study. Valdecantos et al. (Diabetes 2024) gave both compounds to obese rats. The combination produced greater weight loss than either compound alone at sub-maximal doses. No human trial has tested the combination as of June 2026. CagriSema (cagrilintide + semaglutide) is the closest human analog with Phase 3 data.
How does this stack compare to CagriSema?
CagriSema pairs cagrilintide with semaglutide (a GLP-1-only drug). It has Phase 3 REDEFINE-1 data showing about 22.7% weight loss at 68 weeks, and an NDA was filed with FDA in December 2025. Cagrilintide + tirzepatide swaps semaglutide for tirzepatide, which adds GIP receptor activity. The cag + tirz combination covers three pathways instead of two, but it has no human trial data of its own.
How do you reconstitute cagrilintide and tirzepatide?
Reconstitute each vial separately with bacteriostatic water. A common setup is tirzepatide 10 mg + 1.0 mL BAC (= 10 mg/mL; a 5 mg dose = 0.50 mL = 50 units on a U-100 syringe) and cagrilintide 5 mg + 2.0 mL BAC (= 2.5 mg/mL; a 1 mg dose = 0.40 mL = 40 units). Inject BAC water slowly down the vial wall and swirl gently—never shake cagrilintide.
Open the reconstitution calculator →